Fosun Pharma, CanSino take different paths as Covid lift fade
The pair of companies that got strong shots from different Covid vaccines are telling different stories in their latest quarterly results as the pandemic draws down Key Takeaways: Fosun Pharma’s…
CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough
Drugmaker CSPC Pharma gets the green light to produce China’s first homegrown mRNA vaccine, but the breakthrough comes too late in the pandemic to impress investors Key Takeaways: News of…
Fosun Pharma Sells Down BioNTech Stake, Though Divorce Looks Unlikely
The Chinese company profited handsomely from its investment in the German vaccine maker, and is most likely selling the stake to help service its parent’s large debtKey Takeaways:Fosun Pharma said…
FAST NEWS: Fosun Pharma Raises $660 Million in Non-public Placement of A-Shares
The latest: Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) announced on Wednesday it plans to raise up to 4.48 billion yuan ($660 million) through a non-public offering of about…
CanSino’s Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?
The company’s Convidecia has received emergency-use authorization from the World Health Organization, becoming the third Chinese vaccine to get that nod Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted…
AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt
Vaccine maker’s previous IPO bids on Shenzhen’s ChiNext board and in Hong Kong failed, but it is soldiering ahead with a new attempt in Hong Kong Key takeaways: Vaccine maker AIM…
Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins
Company licensed to sell BioNTech’s mRNA vaccine in China reported its revenue rose 28.8% last year, with the Comirnaty vaccine bringing in over $157 million Key takeaways: Fosun Pharma’s revenue…
Recent Articles
RELATED ARTICLES
-
Health Guard plans dual listing to fund HPV vaccine fight
-
Fosun Tourism at crossroads as parent shops its two major assets
1992.HK 0656.HK
-
Fosun International on cusp of new ‘asset-light’ era with latest sale
0656.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Fosun Tourism embarks on new journey with departure of big-name director
1992.HK
-
Shunned by investors, Henlius hangs up on its Hong Kong listing
2696.HK
